The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2024 | NC410 and pembrolizumab in MSS/MSI-L colorectal (CRC) and ovarian cancer
Eric Christenson, MD, John Hopkins Medicine, Baltimore, MD, discusses findings from the Phase Ib/II study (NCT05572684) of NC410 with pembrolizumab in advanced metastatic MSS/MSI-L colorectal (CRC) and ovarian cancer. NC410, a dimeric LAIR-2 protein targeting the extracellular matrix (ECM) designed to enhance immune cell infiltration and counter LAIR-1-mediated immunosuppression, was shown to be well tolerated with promising clinical activity, including partial responses and durable stable disease, and evidence of ECM remodeling. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consulting or Advisory Role – Seres Therapeutics
Research Funding – Haystack Oncology; Pfizer
Other Relationship – Natera
